Treatment of dry age-related macular degeneration with dobesilate

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Cuevas, P ^a   Outeirino L A ^b   Angulo, J ^a   Gimenez Gallego G ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Hospital de Día Pío XII   (Spain)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIHYDROXYBENZENESULFONIC ACID; ETAMSYLATE;

ADULT; ARTICLE; CASE REPORT; ELECTRORETINOGRAM; HUMAN; MALE; MITOGENESIS; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PHOTORECEPTOR INNER SEGMENT; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; THICKNESS; TREATMENT DURATION; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

EID: 84864715446     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.02.2012.5942     Document Type: Article

References (35)

1. Green WR. Histopathology of age-related macular degeneration. Mol Vis 1999;5:27.
2. Fleckenstein M, Charbel Issa P, Helb HM, et al. High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:4137-44.
3. Brar M, Kozak I, Cheng L, et al. Correlation between spectral-domain optical coherence tomography and fundus autofluorescence at the margins of geographic atrophy. Am J Ophthalmol 2009;148:439-44.
4. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina (Philadelphia, Pa) 2004;24(5 Suppl):S3-19.
5. Fernández IS, Cuevas P, Angulo J, et al. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem 2010;285:11714-29.
6. Gehrs KM, Anderson DH, Johnson LV, et al. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med 2006;38:450-71.
7. Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. N Engl J Med 2000;342:483-92.
8. Rodrigues EB. Inflammation in dry age-related macular degeneration. Ophthalmologica 2007;221:143-52.
9. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008;68:1029-36.
10. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58:353-63.
11. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol 2008;30:97-110.
12. Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med 2008;14:194-8.
13. Buschini E, Piras A, Nuzzi R, et al. Age related macular degeneration and drusen: neuroinflammation in the retina. Prog Neurobiol 2011;95:14-25.
14. Telander DG. Inflammation and age-related macular degeneration (AMD). Semin Ophthalmol 2011;26:192-7.
15. Wang J, Ohno-Matsui K, Yoshida T, et al. Amyloid-beta up-regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: Another mechanism of complement activation in age-related macular degeneration. J Cell Physiol 2009;220:119-28.
16. Ma W, Zhao L, Wong WT. Microglia in the outer retina and their relevance to pathogenesis of age-related macular degeneration. Adv Exp Med Biol 2012;723:37-42.
17. Araujo DM, Cotman CW. Basic FGF in astroglial, microglial, and neuronal cultures: characterization of binding sites and modulation of release by lymphokines and trophic factors. J Neurosci 1992;12:1668-78.
18. Liu X, Mashour GA, Webster HF, et al. Basic FGF and FGF receptor 1 are expressed in microglia during experimental autoimmune encephalomyelitis: temporally distinct expression of midkine and pleiotrophin. Glia 1998;24:390-7.
19. Lee M, Kang Y, Suk K, et al. Acidic fibroblast growth factor (FGF) potentiates glial-mediated neurotoxicity by activating FGFR2 IIIb protein. J Biol Chem 2011;286:41230-45.
20. Streilein JW, Ma N, Wenkel H, et al. Immunobiology and privilege of neuronal retina and pigment epithelium transplants. Vision Res 2002;42:487-95.
21. Zamiri P, Sugita S, Streilein JW. Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem Immunol Allergy 2007;92:86-93.
22. Lee JE, Liang KJ, Fariss RN, et al. Ex vivo dynamic imaging of retinal microglia using time-lapse confocal microscopy. Invest Ophthalmol Vis Sci 2008;49:4169-76.
23. Ng TF, Streilein JW. Light-induced migration of retinal microglia into the subretinal space. Invest Ophthalmol Vis Sci 2001;42:3301-10.
24. Xu H, Chen M, Manivannan A, et al. Age-dependent accumulation of lipofuscin in perivascular and subretinal microglia in experimental mice. Aging Cell 2008;7:58-68.
25. Gupta N, Brown KE, Milam AH. Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Exp Eye Res 2003;76:463-71.
26. Giménez-Gallego G, Rodkey J, Bennett C, et al. Brain-derived acidic fibroblast growth factor: complete amino acid sequence and homologies. Science 1985;230:1385-8.
27. Byrd VM, Ballard DW, Miller GG, et al. Fibroblast growth factor-1 (FGF-1) enhances IL-2 production and nuclear translocation of NF-kappaB in FGF receptor-bearing Jurkat T cells. J Immunol 1999;162:5853-9.
28. Meij JT, Sheikh F, Jimenez SK, et al. Exacerbation of myocardial injury in transgenic mice overexpressing FGF-2 is T cell dependent. Am J Physiol Heart Circ Physiol 2002;282:H547-55.
29. Rossini M, Cheunsuchon B, Donnert E, et al. Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease. Kidney Int 2005;68:2621-8.
30. Zittermann SI, Issekutz AC. Basic fibroblast growth factor (bFGF, FGF-2) potentiates leukocyte recruitment to inflammation by enhancing endothelial adhesion molecule expression. Am J Pathol 2006;168:835-46.
31. Bussolino F, Biffignandi P, Arese P. Platelet-activating factor-a powerful lipid autacoid possibly involved in microangiopathy. Acta Haematol 1986;75:129-40.
32. Piller NB. Assessment of the anti-inflammatory action of calcium dobesilate. Effect on macrophages attaching to subcutaneously implanted coverslips in guinea pigs. Arzneimittelforschung 1990;40:698-700.
33. Wollina U, Abdel-Naser MB, Mani R. A review of the microcirculation in skin in patients with chronic venous insufficiency: the problem and the evidence available for therapeutic options. Int J Low Extrem Wounds 2006;5:169-80.
34. Allain H, Ramelet AA, Polard E, et al. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004;27:649-60.
35. Haritoglou C, Gerss J, Sauerland C, et al.; CALDIRET study group. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2009;373:1364-71.